Budget Woes Stall Clinical Trials and Stymie Sites

Bio-IT World By Ann Neuer   February 21, 2012 | Imagine buying a new car or a new house but not knowing the price until the papers have already been drawn up and it’s time to sign on the dotted line.  According to Christine Pierre, President of RxTrials, that’s exactly the situation investigative sites face as they attempt to negotiate budgets and contracts for clinical trials.

“The budget still comes so late in the study start up process for the site.  We’ve been trying to address this for more than two decades, and here it is 25 years later, and we still are being asked to consider studies and go through site selection, the pre-site visit and regulatory process before we have the budget in front of us.  It makes no business sense,” Pierre says. Read More